Metagenomi, Inc. (NASDAQ:MGX) Holdings Decreased by Citadel Advisors LLC

Citadel Advisors LLC lowered its position in Metagenomi, Inc. (NASDAQ:MGX - Free Report) by 81.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 149,698 shares of the company's stock after selling 654,764 shares during the quarter. Citadel Advisors LLC owned about 0.40% of Metagenomi worth $540,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in Metagenomi by 73.8% in the fourth quarter. Geode Capital Management LLC now owns 587,421 shares of the company's stock worth $2,121,000 after buying an additional 249,390 shares during the period. Peapod Lane Capital LLC bought a new stake in Metagenomi in the 4th quarter worth approximately $1,268,000. Rhumbline Advisers grew its position in Metagenomi by 123.3% in the 4th quarter. Rhumbline Advisers now owns 11,998 shares of the company's stock worth $43,000 after purchasing an additional 6,626 shares during the period. Wells Fargo & Company MN grew its position in shares of Metagenomi by 54.5% during the 4th quarter. Wells Fargo & Company MN now owns 95,188 shares of the company's stock valued at $344,000 after acquiring an additional 33,582 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Metagenomi during the 4th quarter valued at $43,000.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Chardan Capital decreased their price target on shares of Metagenomi from $13.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. Wells Fargo & Company reiterated an "overweight" rating and set a $16.00 price objective (down from $20.00) on shares of Metagenomi in a research note on Wednesday, May 14th. Wall Street Zen cut shares of Metagenomi from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Finally, HC Wainwright cut their price objective on shares of Metagenomi from $14.00 to $7.00 and set a "buy" rating on the stock in a research note on Thursday, April 3rd. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Metagenomi presently has a consensus rating of "Moderate Buy" and an average price target of $13.00.

Metagenomi Stock Down 2.4%

NASDAQ:MGX traded down $0.04 during trading hours on Thursday, reaching $1.66. 285,367 shares of the company's stock were exchanged, compared to its average volume of 795,151. The firm has a market capitalization of $62.05 million, a price-to-earnings ratio of -0.79 and a beta of -0.33. Metagenomi, Inc. has a 1-year low of $1.23 and a 1-year high of $6.90. The company has a 50-day moving average of $1.57 and a 200 day moving average of $2.24.

Metagenomi (NASDAQ:MGX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.06). Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. The firm had revenue of $4.13 million for the quarter, compared to analyst estimates of $8.75 million. Research analysts forecast that Metagenomi, Inc. will post -2.46 EPS for the current fiscal year.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.